PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.

Afsar Ali Mian,Anahita Rafiei,Isabella Haberbosch,Alexey A. Zeifman,Ilya Yu. Titov,Victor S. Stroylov,Anna Metodieva,Oleg V. Stroganov,Fedor N. Novikov,Boris Brill,Ghermes G. Chilov,D. Hoelzer,Oliver G. Ottmann,Martin Ruthardt

PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.

2015

Afsar Ali Mian
Anahita Rafiei
Isabella Haberbosch
Alexey A. Zeifman
Ilya Yu. Titov
Victor S. Stroylov
Anna Metodieva
Oleg V. Stroganov
Fedor N. Novikov
Boris Brill
Ghermes G. Chilov
D. Hoelzer
Oliver G. Ottmann
Martin Ruthardt

PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation

Keywords:

Cancer research
Genetics
Philadelphia Chromosome Positive
ABL
breakpoint cluster region
Mutation
Biology
Ponatinib
Kinase
Tyrosine kinase
Leukemia
Mutant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations